Cocrystal Pharma financials
$1.12−7.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | $2.0M | $6.6M | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | $2.0M | $6.6M | $0.00 |
| Gross margin | — | — | — | — | — | 100.0% | 100.0% | — |
| Operating income | -$9.0M | -$17.9M | -$18.6M | -$38.8M | -$14.2M | -$9.6M | -$48.4M | -$62.9M |
| Net income | -$8.8M | -$17.5M | -$18.0M | -$38.8M | -$14.2M | -$9.6M | -$48.2M | -$49.0M |
| Net margin | — | — | — | — | — | −479.0% | −733.8% | — |
| Diluted EPS | $-0.78 | $-1.72 | $-1.87 | $-4.77 | $-1.93 | $-2.04 | $-18.12 | $-21.00 |
| EBITDA | -$8.9M | -$17.8M | -$18.4M | -$19.6M | -$14.0M | -$9.4M | -$2.0M | -$9.0M |
| Operating cash flow | -$8.2M | -$16.5M | -$14.7M | -$21.4M | -$12.7M | -$9.8M | -$1.6M | -$8.3M |
| Free cash flow | -$8.2M | -$16.5M | -$14.8M | -$21.5M | -$12.8M | -$10.1M | -$1.7M | -$8.3M |
| Diluted shares | 11.3M | 10.2M | 9.7M | 8.1M | 7.4M | 4.6M | 2.7M | 2.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.0M | $9.9M | $26.4M | $37.1M | $58.7M | $33.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $7.0K | $34.0K | $73.0K |
| Total assets | $9.7M | $13.5M | $31.3M | $40.8M | $79.4M | $54.2M |
| Total liabilities | $3.4M | $3.9M | $4.9M | $1.3M | $1.8M | $1.7M |
| Shareholders' equity | $6.3M | $9.5M | $26.4M | $39.6M | $77.5M | $52.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology